Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated price target is $24.00.
Andrew Fein has given his Buy rating to Vigil Neuroscience Inc due to a combination of factors. These include the potential for the company’s vMRI and NfL data to provide insight into the mechanisms of action of VGL-101, its flagship drug candidate. Despite the patients being symptomatic, Fein believes that there is a strong genetic basis for the CSF1R signaling pathway, which could lead to a slowing down in the white matter lesion load. This could help establish proof of concept for the program. Moreover, Fein notes that natural history data indicates the potential for a significant change in brain tissue volume in symptomatic patients over a six-month period.
Additionally, Fein views the positive NfL data as beneficial for Vigil in terms of accelerated approval. The CSF and serum NfL data could also be critical in understanding disease modification. Similar to the drug tofersen, a significant reduction in NfL levels could be interesting from a regulatory perspective, possibly allowing Vigil to file for accelerated approval based on the NfL data. Fein also mentions the soundness of the Phase 2 design based on the natural history study in ALSP and the disease mechanism. He believes that the key inclusion criteria for the trial, which include validation of CSF1R mutation, are positive for the program. He does not anticipate unexpected safety issues with VGL101, given the completed dosing of the 60mg/Kg SAD and MAD cohorts and the addition of a 40mg/Kg dose cohort in Phase 2.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $23.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Vigil Neuroscience Inc (VIGL) Company Description:
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.
Read More on VIGL:
- Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
- Arm initiated, SQM downgraded: Wall Street’s top analyst calls
- Vigil Neuroscience initiated with an Outperform at JMP Securities
- Vigil Neuroscience announces first patient dosed in Phase 1 trial of VG-3927
- Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
